Intracameral triamcinolone acetonide as treatment for endothelial allograft rejection after penetrating keratoplasty

Cornea

Volumn 27, Issue 7, 2008, Pages 847-850

  Maris Jr , Peter J G ^a,b,e   Correnti, Anthony J ^a   Donnenfeld, Eric D ^c,d  

^a NASSAU UNIVERSITY MEDICAL CENTER   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c OPHTHALMIC CONSULTANTS OF LONG ISLAND   (United States)

^d EAR AND THROAT HOSPITAL   (United States)

^e Edward S Harkness Eye Institute   (United States)

Author keywords

Endothelial allograft rejection; Intracameral triamcinolone acetonide; Penetrating keratoplasty

Indexed keywords

EYE DROPS; GATIFLOXACIN; GENTAMICIN; LIDOCAINE; PREDNISOLONE ACETATE; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRIAMCINOLONE ACETONIDE; VANCOMYCIN; GLUCOCORTICOID;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CASE REPORT; CELL INFILTRATION; CORNEA EDEMA; CORNEA ENDOTHELIUM; CORNEA NEOVASCULARIZATION; CORNEA STROMA; CORNEA TRANSPLANTATION; CORNEAL ENDOTHELIAL ALLOGRAFT REJECTION; DIFFERENTIAL DIAGNOSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOGRAPHY; FOLLOW UP; GRAFT INFECTION; GRAFT REJECTION; HUMAN; INFLAMMATORY CELL; INTRAOCULAR PRESSURE; KERATITIS; KERATOMETRY; KERATOMILEUSIS; MAINTENANCE THERAPY; MALE; OCULOPLETHYSMOGRAPHY; PATIENT REFERRAL; PENETRATING KERATOPLASTY; PHOTOREFRACTIVE KERATECTOMY; PRIORITY JOURNAL; RETINA; SLIT LAMP; SUTURE; TOPOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS DISEASE; ALLOTRANSPLANTATION; ANTERIOR EYE CHAMBER; DRUG EFFECT; INJECTION; PATHOLOGY; TRANSPLANTATION;

ADULT; ANTERIOR CHAMBER; ENDOTHELIUM, CORNEAL; GLUCOCORTICOIDS; GRAFT REJECTION; HUMANS; INJECTIONS; KERATOPLASTY, PENETRATING; MALE; TRANSPLANTATION, HOMOLOGOUS; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY;

EID: 49849102690     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31816b69f5     Document Type: Article

References (20)

1. Thompson RW Jr, Price MO, Bowers PJ, et al. Long-term graft survival after penetrating keratoplasty. Ophthalmology. 2003;110:1396-1402.
2. Patel SV, Hodge DO, Bourne WM. Corneal endothelium and postoperative outcomes 15 years after penetrating keratoplasty. Am J Ophthalmol. 2005;139:311-319.
3. Coster DJ. Mechanisms of corneal graft failure: the erosion of corneal privilege. Eye. 1989;3:251-262.
4. Rinne JR, Stulting RD. Current practices in the prevention and treatment of corneal graft rejection. Cornea. 1992;11:326-328.
5. Birnbaum F, Bohringer D, Sokolovska Y, et al. Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study. Transplantation. 2005;79:964-968.
6. Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection. Arch Ophthalmol. 1981;99:599-604.
7. Khodadoust AA. The allograft rejection reaction: The leading cause of late failure of clinical corneal grafts. In: Porter R, Knight J, eds. Corneal Graft Failure. Amsterdam: Associated Scientific Publishers; 1973:151-164.
8. Boisjoly HM, Bernard PM, Dube I, et al. Effect of factors unrelated to tissue matching on corneal transplant endothelial rejection. Am J Ophthalmol. 1989;107:647-654.
9. Perry HD, Donnenfeld ED, Acheampong A, et al. Topical cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroidinduced ocular hypertension and the penetration of topical 0.5% cyclosporine A into the cornea and anterior chamber. CLAO J. 1998;24:159-165.
10. Price MO, Price FW. Efficacy of topical cyclosporine 0.05% for prevention of corneal transplant rejection episodes. Ophthalmology. 2006;113:1786-1790.
11. Hill JC, Maske R, Watson P. Corticosteroids in corneal graft rejection. Oral versus single pulse therapy. Ophthalmology. 1991;98:329-333.
12. Hudde T, Minassian DC, Larkin DF. Randomised controlled trial of corticosteroid regimens in endothelial corneal allograft rejection. Br J Ophthalmol. 1999;83:1348-1352.
13. Reinhard T, Sundmacher R. Adjunctive intracameral application of corticosteroids in patients with endothelial immune reactions after penetrating keratoplasty: a pilot study. Transpl Int. 2002;15:81-88.
14. Jonas JB, Kamppeter B. Intravitreal triamcinolone acetonide for persisting cystoid macular edema after penetrating keratoplasty. Cornea. 2006;25: 240-241.
15. Yamakiri K, Uchino E, Kimura K, et al. Intravitreal triamcinolone helps to visualize and remove the vitreous body in anterior chamber in cataract surgery. Am J Ophthalmol. 2004;138:650-652.
16. Benz MS, Albini TA, Holz ER, et al. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology. 2006;113:1174-1178.
17. Rhee DJ, Peck RE, Belmont J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol. 2006;90: 999-1003.
18. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol. 2003;136: 384-386.
19. Singh IP, Sameer IA, Yeh D, et al. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2004;138:286-287.
20. Chang Y-S, Tseng S-Y, Tseng S-H, et al. Triamcinolone acetonide suspension toxicity to corneal endothelial cells. J Cataract Refract Surg. 2006;32:1549-1555.